CD109 and acute myeloid leukemia: A recent study (Deepak et al., 2022) revealed the potential of CD109 as a biomarker with diagnostic capabilities in AML, and this study further aligns with this finding, in which CD109 was also found with the highest specificity and sensitivity with AUC (Figure 4).